Discovering and developing psychedelic pharmaceuticals to treat disorders of the brain and nervous system
TORONTO, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (d/b/a Pharmather) (“ Pharmather ” or the “ Company ”) (CSE: PHRM), a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company's common shares have been approved for listing on the Canadian Securities Exchange (the "CSE") and the Company expects to begin trading on the CSE under the trading symbol "PHRM" as of market open on October 9, 2020.
Fabio Chianelli, Pharmather’s Chief Executive Officer, said, “I am very excited for this milestone, and I would like to thank our team and advisors for their efforts. Special thanks to our shareholders for their support and confidence in Pharmather’s objective in discovering and developing new uses of psychedelic pharmaceuticals for FDA approval for disorders of the brain and nervous system. I look forward to updating the investment community on our developments with panaceAI™, our drug repurposing platform with artificial intelligence, and our advancements with psychedelic compounds such as ketamine and psilocybin towards FDA human clinical trials.”
For more information, please view Pharmather’s corporate presentation or visit www.pharmather.com . To receive regular news updates from Pharmather, subscribe at www.pharmather.com/news .
About Pharmather
Pharmather (CSE: PHRM) is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. Pharmather was founded with a particular focus on repurposing psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Our team includes world-class strategic partners, advisors and a strong leadership team with a proven track record of success in drug development, business development and capital markets. Our goal is to advance the development of panaceAI™, our drug repurposing artificial intelligence platform, and advance our clinical product pipeline with ketamine and psilocybin for Parkinson’s disease, depression, traumatic brain injury and stroke. For more information, visit www.pharmather.com .
For more information, please contact:
Fabio Chianelli
Chief Executive Officer
Pharmather Inc.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Pharmather’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the CSE listing, panaceAI ™ and product developments. Forward-looking information is based on reasonable assumptions that have been made by Pharmather at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Pharmather is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Pharmather’s management’s discussion and analysis for the period of August 30, 2020 (“MD&A”), dated October 1, 2020, which is available on Pharma t her’s profile at www.sedar.com .
This new s release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
